Drugs / CDI-31244
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02760758 | Apr 2016 → Mar 2017 | hepatitis C virus infection | Cocrystal Pharma, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03794258 | May 2019 → Apr 2020 | hepatitis C virus infection | Humanity & Health Medical Group Limited | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03501550 | Jun 2018 → Jan 2019 | chronic hepatitis C virus infection | Cocrystal Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDI-31244 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02760758 ↗ |
| Action | Inhibit | “CDI-31244 (non-nucleoside inhibitor or NNI)” NCT03501550 ↗ |
| Route | Oral | “orally administered CDI-31244” NCT02760758 ↗ |